Firmagon

【Function and indication】
Firmagon is a GnRH receptor antagon used to treat patients with advanced prostate cancer.

【Model and specification】
Firmagon (degarelix injection) 80 mg per vial; Firmagon (degarelix injection) 120 mg per vial.

【Usage and dosage】
Firmagon is injected subcutaneously and cannot be administered intravenously. The starting dose of treatment is injected, 120 mg to 240 mg each time. This is followed by maintenance administration as a single injection, with a starting dose of 80 mg every 28 days.

【Clinical study】
Firmagon (degarelix) is a GnRH receptor antagon used to treat patients with advanced prostate cancer. The most common adverse reactions during Firmagon treatment include injection site reactions (such as pain, erythema, swelling, or nodules), hot flashes, weight gain, and increased serum transaminases and gamma-glutamase (GGT).

【Precautions】
Long-term androgen deprivation therapy prolongs the QT interval. Consider the risks and benefits.

【Adverse Reactions and Contraindications】
The most common adverse reactions (>10%) during Firmagon treatment include injection site reactions (such as pain, erythema, swelling, or nodules), hot flashes, weight gain, and increased serum transaminases and gamma-glutamylase (GGT).

【Drug Interactions】
Clinically significant cytochrome P450 pharmacokinetic drug interactions are unlikely.

【Manufacturer】
Denmark